The fixed combination of valerian and hops (Ze91019) acts via a central adenosine mechanism

Planta Medica

Volumn 70, Issue 7, 2004, Pages 594-597

  Schellenberg, R ^a   Sauer, S ^a   Abourashed, E A ^b   Koetter, U ^c   Brattstrom A ^d,e  

^a Inst F Ganzheitliche Med Wiss   (Germany)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c GLAXOSMITHKLINE   (United States)

^d Zeller AG   (Switzerland)

^e Zeller Medical AG   (Switzerland)

Author keywords

Caffeine; Cannabaceae; EEG; Humulus lupulus; Interaction; Valerian hop extract combination; Valeriana officinalis; Valerianaceae

Indexed keywords

ADENOSINE; ADENOSINE RECEPTOR; ADENOSINE RECEPTOR BLOCKING AGENT; ADENOSINE RECEPTOR STIMULATING AGENT; CAFFEINE; HUMULUS LUPULUS EXTRACT; PLACEBO; VALERIAN; ZE 91019;

ADULT; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG COMPETITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; ELECTROENCEPHALOGRAM; HUMAN; HUMAN EXPERIMENT; HUMULUS LUPULUS; MALE; NORMAL HUMAN; SLEEP INDUCTION; VALERIANA OFFICINALIS;

ADMINISTRATION, ORAL; ADULT; CAFFEINE; CENTRAL NERVOUS SYSTEM; ELECTROENCEPHALOGRAPHY; HUMANS; HUMULUS; MALE; PHYTOTHERAPY; PLANT EXTRACTS; PLANT ROOTS; RECEPTOR, ADENOSINE A2A; VALERIANACEAE;

CANNABACEAE; HUMULUS; HUMULUS LUPULUS; VALERIANA; VALERIANA OFFICINALIS; VALERIANACEAE;

EID: 3543004166     PISSN: 00320943     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2004-827180     Document Type: Article

References (23)

1. Vonderheid-Guth B, Todorova A, Brattström A, Dimpfel W. Pharmacodynamic effects of valerian and hops extract combination (Ze91019) on the quantitative-topographical EEG in healthy volunteers. Eur J Med Res 2000; 5: 139-44
2. Rodenbeck A, Simen S, Cohrs S, Jordan W Kinkelbur J, Staedt J, Hajak G. Veränderte Schlafstadienstruktur als Hinweis auf die CABAerge Wirkung eines Baldrian-Hopfenpräparates bei Patienten mit psychophysiologischer Insomnie. Somnologie 1998; 2: 26-31
3. Füssel A, Wolf A, Brattström A. Effect of a fixed valerian-hop extract combination (Ze91019) on sleep polygraphy in patients with non-organic insomnia: a pilot study. Eur J Med Res 2000; 5: 385-90
4. Basheer R, Porkka-Heiskanen T, Strecker RE, Thakkar MM, McCarley RW. Adenosine as a biological signal mediating sleepiness following prolonged wakefulness. Biological Signals and Receptors 2000; 9: 319-27
5. Strecker RE, Morairty S, Thakkar MM, Porkka-Heiskanen T, Basheer R, Dauphin L, Rainnie DG, Portas CM, Greene RW, McCarley RW. Adenosinergic modulation of basal forebraisn and preoptic/anterior hypothalamic neuronal activity in the control of behavioral state. Behavioural Brain Res 2000; 115: 183-204
6. 2A receptor mRNA in the rat following sleep deprivation. Sleep 2001; 12: 1577-80
7. 6-cyclohexylandenosine binding to rat cortical membranes by hydroalcoholic extract of Valeriana officinalis. Med Sci Res 1989; 17: 639-40
8. Koetter U, Abourashed EA, Brattström A, Schellenberg R. Effect of a fixed valerian-hops extract combination (Ze 91019) on quantitative EEG data in healthy subjects with caffeine induced hyper-arousal. Sleep 2002; 25: A46
9. Müller CE, Schumacher B, Brattström A, Abourashed EA, Koetter U. Interaction of valerian extracts and a fixed valerian-hop extract combination with adenosine receptors. Life Science 2002; 71: 1939-49
10. Schumacher B, Scholle S, Hölzl J, Khudeir N, Hess S, Müller CE. Lignans isolated from valerian: identification and characterization of a new olivil derivative with partial agonistic activity at A1 adenosine receptors. J Nat Prod 2002; 65: 1479-85
11. Kochmann M, Kunz H. Über die Wirkung des Baldrian und eine Methode der Wertbestimmung. Arch Exp Path Pharmakol 1936; 181: 421-34
12. Haffner F. Die pharmakologische Wertbestimmung des Baldrian. Münchner Med Wochenschrift 1929; 7: 271-272
13. Werz v. R, Homann G. Über die Prüfung von Beruhigungsmitteln am Menschen. Arch Exp Path Pharmakol 1939; 193: 272-280
14. Karacan I, Thornby JI, Anch AM, Booth GH, Williams RL, Salis PJ. Dose-related sleep disturbances induced by coffee and caffeine. Clin Pharmacol Therapeutics 1977; 20: 682-9
15. Pollak CP, Bright D. Caffeine consumption and weekly sleep patterns in US seventh-, eighth-, and ninth-graders. Pediatrics 2003; 111: 42-6
16. Schellenberg R, Schwarz A, Knorr W, Haufe C. EEG-brain mapping - a method to optimize therapy in schizophrenics using absolute power and center frequency values. Schizophrenia Res 1992; 8: 21-9
17. Schellenberg R, Todorova A, Dimpfel W, Schober F. Pathophysiology and psychopharmacology of dementia - a new study design. Diagnosis comprising subjective and objective criteria. Neuropsychobiology 1985; 32: 81-97
18. Schellenberg R, Sauer S, Dimpfel W. Pharmacodynamic effects of two different Hypericum extracts in healthy volunteers measured by quantitative EEG. Pharmacopsychiatry 1998; 31: 44-53
19. Dimpfel W, Schober F, Spüler M. The influence of caffeine on human EEG under resting conditions and during mental loads. Clin Investig 1993; 71: 197-207
20. Benowitz NL. Clinical pharmacology of caffeine. Ann Rev Med 1990; 41: 277-288
21. Saletu B, Anderer P, Kinsberger K et al. Topographic brain mapping of EEG in neuropsychopharmacology. II. Clinical applications (pharmaco EEG imaging). Methods Find Exp Clin Parmacol 1987; 9: 385-408
22. Schulz H, Jobert M, Hübner WG. The quantitative EEG as a screening instrument to identify sedative effects of single doses of plant extracts in comparison with diazepam. Phytomedicine 1998; 5: 449-58
23. Hasenfratz M, Bättig K. Acute dose-effect relationships of caffeine and mental performance, EEG, cardiovascular and subjective parameters. Psychopharmacology 1994; 114: 281-7